Whether olaparib (lipadro) needs to be taken for life and long-term safety assessment

Olaparib is an oral polyADPribose polymerase (PARP) inhibitor. It is mainly used to treat patients with advanced ovarian cancer, breast cancer, prostate cancer and pancreatic cancer with BRCA mutations. By inhibiting theDNA repair pathway, tumor cells accumulate DNA damage and die. Olaparib is usually used for maintenance treatment or second-line and multi-line treatment after disease progression. Patients need to take it orally regularly for a long time under the guidance of a doctor to maintain the efficacy and delay tumor recurrence.

Not all patients need to take olaparib for life, and its course of treatment depends on the type of disease, efficacy and patient tolerance. In maintenance treatment of ovarian cancer, it is generally recommended to continue taking medication until disease progression or intolerable side effects occur. For some patients with prostate cancer or breast cancer, if long-term remission is achieved and the tumor is stable, the treatment course may be adjusted or the medication may be temporarily discontinued after the doctor's evaluation. Therefore, the use cycle of Lynparza should be individually customized and should not be taken blindly for a long time.

Common adverse reactions of long-term use of olaparib include anemia, fatigue, nausea, decreased appetite and thrombocytopenia. Most side effects are mild to moderate and can be alleviated by dose adjustment or symptomatic treatment. Long-term monitoring of blood routine, liver and kidney function, and cardiovascular status is very important to avoid serious complications. Clinical data show that long-term oral olaparib is generally well tolerated, but some patients may develop bone marrow suppression, secondary leukemia or pulmonary adverse reactions, which need to be treated in a timely manner under the guidance of a professional doctor.

During long-term medication, doctors should develop individualized plans based on patient efficacy evaluation and side effects. For mild to moderate side effects, you can continue taking the medication and adjust the dose; for severe side effects, you need to suspend the medication, adjust the dose, or take supportive care. Patients should undergo regular imaging review, hematology and organ function monitoring, and also pay attention to lifestyle management, such as maintaining balanced nutrition, moderate exercise and adequate rest. Through scientific management and individualized adjustment, olaparib can achieve long-term maintenance of efficacy and improve patient survival benefits while ensuring safety.

Reference materials:https://www.drugs.com/

xa0